# NCT01436968 (NCT01436968)

> Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: aglatimagene besadenovec (CAN-2409)
- Indication: localized prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01436968
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Candel Therapeutics, Inc.
- Conditions: Prostate Cancer
- Interventions: Aglatimagene besadenovec + valacyclovir; Placebo + valacyclovir
- Enrollment: 711
- Primary outcome: Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.

## Indexed commentary on NCT01436968 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01436968